Quote:

---

"As previously announced, CytoDyn is preparing a manuscript summarizing the integrated safety data from the almost 1,600 patients who have already received leronlimab. The final draft of that safety summary will be complete shortly.”

Any idea as to what these anticipated results would mean to the FDA? Would safety still need to be exhibited for every indication in future trials?

---

What is has meant for us prior to the safety hold is that we could go straight to phase 2 trials and that will continue.